LUND, Sweden, Nov. 9, 2020 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) today announced that
it will present data from three immuno-oncology projects at the
Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual
Meeting, November 9-14, 2020.
The presentations will include the Phase I study of ATOR-1015,
the Phase I-ready ALG.APV-527 developed in partnership with Aptevo
Therapeutics, as well as the novel bispecific concept
Neo-X-Prime.
"The fact that three of our immuno-oncology projects have been
selected for presentation at this year's SITC is a clear
confirmation of Alligator's strong presence in the field. The
presentations span from advanced clinical patient data to thrilling
early data from our next generation drug concept Neo-X-Prime", said
Per Norlén, CEO at Alligator Bioscience.
Abstracts are available on the SITC website and the
accompanying posters will be available in the Virtual Poster Hall
open from 8:00 am ET on Monday, Nov.
9, until the Virtual Poster Hall closes on Dec. 31, 2020. The posters are also posted on the
Alligator Bioscience website.
Title: Safety and pharmacodynamic activity of
ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a Phase I dose
escalation study of patients with advanced solid
malignancies
Poster summary: ATOR-1015 is currently evaluated in
clinical Phase I at a flat dose of 750 mg, which is the highest
dose to be evaluated in the ongoing study. One dose limiting
toxicity (infusion related reaction) has been observed at 750 mg.
No severe immune-related adverse events have been reported. Best
clinical response is stable disease.
Details of the presentation: Live question and answer
sessions will occur for the ATOR-1015 poster (Number 369) on
Wednesday, Nov. 11, from 5:15 to 5:45 p.m. ET and Friday, Nov. 13, from 4:20
to 4:50 p.m. ET.
Title: ALG.APV-527: Potent tumor-directed T cell
activation and in vivo tumor inhibition induced by a 4-1BB x 5T4
ADAPTIR™ bispecific antibody
Poster summary: The presentation covers preclinical data
demonstrating that ALG.APV-527 has a favorable safety profile with
no indications of systemic immune activation or liver toxicity. In
experimental disease models, ALG.APV-527 increased anti-tumor
responses and promoted tumor-specific memory. Clinical development
is planned for ALG.APV-527 and CTA documents are prepared for
filing of a Phase I clinical trial in the EU.
Details of the presentation: Live question and answer
sessions will occur for the ALG.APV-527 poster (Number 851) on
Wednesday, Nov. 11, from 5:15-5:45 p.m. ET and Friday, Nov. 13, from 4:40-5:10 p.m. ET.
Title: A bispecific antibody targeting CD40 and EpCAM
induces superior anti-tumor effects compared to the combination of
monospecific antibodies
Poster summary: The presentation will cover the
Neo-X-Prime bispecific prototype antibody targeting CD40 and EpCAM.
Neo-X-Prime induces superior anti-tumor effects compared to a
combination of monotargeting compounds. Furthermore, Neo-X-Prime
induces a broad immunological memory against tumor antigens.
Details of the presentation: Live question and answer
sessions will occur for the Neo-X-Prime poster (Number 858) on
Thursday, Nov. 12, from 4:50-5:20 p.m. ET and Saturday, Nov. 14, from 1-1:30 p.m. ET.
For further information, please contact:
Cecilia Hofvander, Director Investor
Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
The information was submitted for publication, through the
agency of the contact person set out above, at 2:00 p.m. CET
on November 9, 2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes the two key assets ATOR-1017 and
mitazalimab. Furthermore, there are two partnered assets:
ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and
AC101 in clinical development by Shanghai Henlius Biotech Inc.). In
addition, the company has developed a novel concept for more
patient-specific immunotherapy: Neo-X-Prime. Alligator's shares are
listed on Nasdaq Stockholm (ATORX). The Company is headquartered in
Lund, Sweden. For more
information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-presents-at-the-sitc-35th-annual-meeting,c3233698
The following files are available for download:
https://mb.cision.com/Main/12681/3233698/1332462.pdf
|
Alligator Bioscience
presents at the SITC 35th Annual Meeting
|
View original
content:http://www.prnewswire.com/news-releases/alligator-bioscience-presents-at-the-sitc-35th-annual-meeting-301168651.html
SOURCE Alligator Bioscience